-
US envoys in Moscow as Russia and Ukraine vow not to hit capitals during talks
-
US military says destroys Iranian oil tankers after missile attacks
-
Motorsport governing body rejects Alpine boss's claims of bias
-
US envoys in Moscow for Ukraine war negotiations
-
US envoy on West Bank visit says Israel has responsibility for Palestinians
-
Commemoration held for late Serbian war criminal Ratko Mladic
-
Ethiopian Miss World contestant spotlights pain of sister's murder
-
Russell on top ahead of Hamilton in final Italian GP practice
-
'Leader' Raphinha rising to Barca striker challenge
-
Motorsport governing body rejects Alpine boss's claims of impartiality
-
Oasis fans gather in Venice for band reunion film
-
Flick hoping Barca's Yamal can face Valencia after knock
-
Two Nepal rescues revive hopes 10 days after flood
-
Trump envoys land in Moscow for Russia-Ukraine peace push
-
Pogacar to miss worlds after season-ending Vuelta crash
-
Russia hits Kyiv airports as Trump peace envoys awaited
-
Greenwood, Guendouzi handed bans after Fenerbahce-Lyon brawl
-
Nepal tunnel rescue revives hopes 10 days after flood
-
In Iceland, the mystery of the poet, the tomb and the Danish grocer
-
Indonesia rescues second orangutan mother and baby from wildfire
-
Ratko Mladic: Bosnian Serb commander to convicted war criminal
-
Box office magnet Robert Pattinson appears in paedophile thriller
-
Bolivian army base blasts kill two, wound dozens
-
How haze from Indonesian fires impacts Southeast Asia
-
Alcaraz, Sabalenka into US Open last 16 as Williams sisters lose on return
-
Trump sends envoys to Moscow, Kyiv with new plan to 'end war'
-
Williams sisters fall in thrilling return to US Open doubles
-
'Mini-dictatorship': Students slam Argentina-run residence in Paris
-
Bangladesh measles toll nears grim 1,000-child mark
-
The disgraced banker stirring the pot in Brazil's Supreme Court
-
Bolivia farmers return to streets over diesel price hikes
-
New to The Street Broadcasts at 6:30 PM ET Across Bloomberg U.S., Latin America and MENA, Featuring Lantern Pharma (NASDAQ:LTRN), SafeSpace Global (OTCID:SSGC) and FreeCast (NASDAQ:CAST)
-
Panama Canal begins reducing crossings due to El Nino
-
Tetris distances itself from controversial White House 'arcade' games
-
Trump again seeks to remove protections for wolves
-
Africa bigger, US smaller - UN adopts new map
-
'Getting there' - Alcaraz into US Open last 16 along with Sabalenka
-
Bad weather will not affect All Blacks, says captain Savea
-
Isak ready to show world his quality, says Van Dijk
-
Mbappe misses penalty as Parrott lifts Betis past Real Madrid
-
Stuttgart cruise past Cologne to bounce back from Bayern thumping
-
PSG still winless in Ligue 1 as Monaco go top
-
'Smart, aggressive' Alcaraz into US Open last 16
-
Defending champion Alcaraz reaches last 16 at US Open
-
Isak fires Liverpool to first win under Iraola at Ipswich
-
Lyles ends season before Budapest due to injury flare ups
-
Stocks slip as robust US jobs data stokes rate hike odds
-
US Republicans announce probe into environment groups
-
Mistrial declared in case of US woman who killed her three children
-
Sabalenka survives despite 'tricky' weed smell at US Open
Retransmission: CTT Pharma and Johns Hopkins University Submits Proposal for $15 Million NIH Grant for Smoking Cessation
TAMPA, FL / ACCESS Newswire / January 28, 2025 / CTT Pharmaceutical Holdings, Inc. (OTC:CTTH) and Johns Hopkins University have successfully submitted our proposal for a NIH Grant that will utilize CTT's patented technology as a smoking cessation product. This grant will allow for clinical trials to be conducted and up to $15 million given to cover these trials. The NIH will begin the review process of this proposal in April 2025 and will notify Johns Hopkins University and CTT Pharma of the results. The CEO of CTT Pharma, Ryan Khouri stated, "This brings us one step closer to helping smokers quit, as 480,000 Americans die every year or 1300 per day from the effects of smoking. The last oral nicotine product that was FDA Approved for smoking cessation was Nicorette gum in 1984. While Nicorette gum has helped many people quit smoking, I believe consumers need more options to quit. CTT's fast acting dissolvable nicotine strips would use substantially less nicotine per dose compared to Nicorette Gum and also dissolve in seconds compared to the gum staying in the mouth for 30 minutes. I also want to price our patented technology at or below the price of Nicorette gum, as pricing of our product should not be a deterrent for a consumer looking to quit smoking. Upon approval from the NIH I'm confident in our teams ability to execute our technology and do not anticipate any problems arising. Johns Hopkins University will be in charge of the clinical trials from start to finish. This past October I attended and briefly spoke at a FDA/NIH hearing about advancing smoking cessation technology. I personally met with many individuals who work for both the FDA and NIH and had productive conversations. Furthermore, I have been asked to appear on Fox Business and Bloomberg for interviews in regards to this grant and have interest in doing both shows. I would prefer to do these interviews once our proposal has been approved but I'm considering doing them beforehand. I firmly believe CTT Pharma's dissolvable nicotine strips are a viable solution to a worldwide problem and should be used as a tool to get people to stop smoking." The World Health Organization states, "The tobacco epidemic is one of the biggest public health threats the world has ever faced, killing over 8 million people a year around the world. More than 7 million of those deaths are results of direct tobacco use while 1.3 million are the result of non-smokers being exposed to second-hand smoke." The CDC says, "Cigarette smoking is the leading cause of preventable death in the United States. Cigarette smoking causes more than 480,000 deaths each year in the United States. This is nearly one in five deaths." CTT will continue to update shareholders as more news becomes available.
Investor Relations - 813-606-0060
SOURCE: CTT Pharmaceutical Holdings, Inc.
View the original press release on ACCESS Newswire
M.O.Allen--AT